Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND

Abstract: Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5-[(2-propyloxy-5-[(1-methyl-2-pyrolidinylenamidosulfonyl)] phenyl)-1-methyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphate (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure.
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
[DESCRIPTION]

Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE

[Technical Field]

The present invention relates to a pharmaceutical composition for treating chronic heart failure (CHF) comprising, as an effective ingredient, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyleneamidosulfonyl) phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one.

[Background Art]

The heart consists of four chambers, two atria (upper chambers) and two ventricles (lower chambers), and four major valves. As the heart beats, the right atrium receives venous blood from the body. The blood then passes through the tricuspid valve to the right ventricle. At the same time, blood oxygenated in the lungs flows into the left atrium and then passes through the mitral valve into the left ventricle. The contraction of the right ventricle propels the blood collected in the right atrium into the lung, in which the venous blood picks up oxygen. Oxygenated blood is returned to the left
atrium and flows down into the left ventricle. The left ventricle contracts to pump the blood to the body. Of the four heart valves, two valves prevent blood from flowing backward between an atrium and a ventricle, and the other two valves prevent the backward flow of blood between a ventricle and an artery. The heart beats to supply blood to all parts of the body. The blood pumped from the heart circulates in the body to deliver oxygen and nutrients to tissues and carries waste products away from tissues. The volume of blood expelled by the heart with each beat varies depending on physical activity. A relatively small volume of blood is required for resting time, while a large volume of blood is needed for exercise. In this way, the heart beats slowly or rapidly according to demands for blood, leading to relaxation and contraction of blood vessels.

Heart failure is a pathophysiologic state in which the heart loses its ability to pump a sufficient amount of blood to meet the needs of the body tissues, and is caused by several factors. When the cardiac muscle is not able to contract or relax forcefully enough, blood circulation becomes difficult, and a larger volume of blood accumulates in each chamber of the heart and the lungs. When this happens, the heart tries to compensate for this by becoming enlarged to pump more blood to tissues or organs. When this state lasts for a long time, the compensation effort reaches its limits, causing more severe problems. In particular, when the pumping capacity of the heart
weakens gradually, this state is called chronic heart failure. The body's methods of compensating for this condition include increased heart rate, heart enlargement (dilation), and fluid retention. Since cardiac decompensation is accompanied by congestion, chronic heart failure is also referred as congestive heart failure.

According to the American Heart Association, heart failure affects about five million Americans, and about 550,000 new cases are diagnosed each year. Also, about 1% of people aged 50 years or older and about 5% of those aged 75 years or older are suffering from heart failure. About 10% of patients diagnosed with heart failure die from heart failure within one year, and 50% of patients die within five years.

Chronic heart failure may be caused by some diseases, and such diseases are deemed as principal causes of the diminished cardiac function. However, other factors may contribute to the development of heart failure in patients who have lived relatively well for a long time even though they have been suffering from a heart failure-causing disease. The common causes of heart failure include excessive afterload and preload, impaired blood flow into the ventricles, defective heart function caused due to myocardial ischemia, and primary myocardial disease. Factors contributing to heart failure include infective endocarditis, acute myocarditis, uncontrolled hypertension, acute myocardial infarction, pulmonary embolism,
various infections, anemia, hyperthyroidism, pregnancy, physical and mental strain, excessive alcohol consumption, and excessive eating.

The symptoms of heart failure vary depending on the severity of the illness, but the most common symptom is breathing difficulty. Difficulty in breathing occurs only during exercise in early stages, but occurs even without physical activity with the progression of heart failure. When someone lies down, breathing becomes more difficult due to the difference in the volume of blood entering the heart. Other symptoms include coughing, wheezing, palpitation, nausea, confusion, enuresis, oliguria, systemic edema, ascites, upper abdominal discomfort, pain and swelling, rapid onset of fatigue, and general weakness.

Heart failure is diagnosed through physical examination, based on personal and family history, or by assessing abnormalities in the left ventricle or the valves. Electrocardiography, echocardiography and cardiac catheterization are performed in order to evaluate cardiac function and detect coronary artery disease and myocardial infarction.

The treatment of chronic heart failure is performed with the removal of contributing factors, the treatment of diseases as fundamental causes, the reduction of dietary salt, the reduction of preload using diuretics, and the reduction of
afterload using vasodilators. Digoxin or sympathomimetic amines, which act to increase myocardial contractibility, are also useful in the treatment of chronic heart failure.

Vasodilators, such as angiotensin-converting enzyme (ACE) inhibitors, nitrates, and hydralazine, are primarily used for treating chronic heart failure. Thiazide or loop diuretics can be given in early stages of therapy because they can reduce fluid retention. Digitalis glycosides have also been used to treat heart failure. Beta blockers, such as carvedilol, metoprolol and bisoprolol, have been reported to be effective in chronic heart failure.

ACE inhibitors activate cGMP, which induces vascular smooth muscle relaxation, to enlarge arterial blood vessels. Of ACE inhibitors, enalapril, captopril and lisinopril increase the survival rates of patients having chronic heart failure, and quinapril and fosinopril alleviate symptoms in patients having left ventricular dysfunction. In this way, ACE inhibitors reduce morbidity and mortality of heart failure patients due to left ventricular dysfunction, and are thus used to treat chronic heart failure. Thus, losartan, acting on the rennin-angiotensin system (RAS), has been expected to have therapeutic effects on heart failure, and clinical trials to date have supported its therapeutic efficacy on chronic heart failure. However, the use of losartan is restricted in the case of hypotension patients, and may affect renal function and potassium levels in the body.
Chronic coughing is observed in 10% of patients. As well, other side effects include dizziness due to low blood pressure, skin rash, and sudden swelling of the lips and cheeks.

Angiotensin II receptor blockers are used in patients who cannot tolerate the side effects of ACE inhibitors. They improve the symptoms of heart failure through an action mechanism similar to that of ACE inhibitors. Trials are underway to examine whether angiotensin II receptor blockers can be used in combination with ACE inhibitors. Angiotensin II receptor blockers do not cause severe side effects when administered in a single dose per day, but rarely cause renal function deterioration.

Beta blockers have been known to worsen the symptoms of heart failure, but are also considered to have beneficial therapeutic effects. They help relax the heart muscle, weaken myocardial contractibility, and reduce additional cardiac strain. The most commonly used beta blockers are carvedilol and metoprolol, which have beneficial actions to prevent the progression of heart failure, shorten hospitalization, and reduce mortality. Beta blockers should be administered starting from a low dosage, and the dosage should be increased gradually over a long period of several months. During several weeks after administration, symptoms often worsen because the oxygen supply to the body decreases. Other side effects include hypotension, breathing difficulty, and nausea.
In addition to the aforementioned drugs, phosphodiesterase III inhibitors, Class III antiarrhythmics, such as amiodarone, implantable cardioverter defibrillators (ICDs), and calcium channel blockers (CCBs), such as amlodipine and felodipine, are used to treat heart failure. ICDs, which have been still studied, have been approved only for use in a high-risk group, and CCBs have been used only in patients having other indications for CCB therapy.

Phosphodiesterase V (PDE-5) inhibitors have been demonstrated to inhibit the enlargement, remodeling and fibrosis of ventricular muscle in mice in which pressure overload was induced by sildenafil (Nature medicine 2005 11(2):214-222). The effects of PDE-5 inhibitors have been known to be achieved via a mechanism which involves blocking of the activity of PDE-5, catalyzing the breakdown of cyclic guanosine monophosphatase (cGMP), coupled with an intrinsic signaling system in the heart, so as to inhibit myocardial proliferative responses (Journal of Biological Chemistry 2003 278:47694-47699).

The present inventors developed prior to this application 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyleamidosulf onyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo (4,3-d)pyrimidine-7-one, designated the compound as "udenafil", and reported that the compound has the effect of inhibiting PDE-5 activity (Korean Pat. Registration
No. 0353014).
The inventors of this application conducted further research on the compound, and the research resulted in new findings that the udenafil compound (also referred herein to as "a pyrazolopyrimidinone derivative") prevents ventricular cavity enlargement and ventricular wall thinning in chronic heart failure. The findings further include that the pyrazolopyrimidinone derivative suppresses the ventricular expression of atrial natriuretic peptide (ANP) mRNA, and reduces the amount of collagen deposition, as a marker of ventricular fibrosis, in ventricles, thereby leading to the present invention.

[Disclosure]

[Technical Problem]

It is therefore an object of the present invention to provide a pharmaceutical composition comprising a pyrazolopyrimidinone derivative as an effective ingredient for a novel use of the compound in the treatment of chronic heart failure.

It is another object of the present invention to provide a pharmaceutical composition for improving depressed cardiac function by suppressing morphological changes in chronically failing hearts, reducing atrial natriuretic peptide (ANP) levels, and inhibiting ventricular fibrosis.
It is a further object of the present invention to provide a pharmaceutical composition for treating chronic heart failure, comprising, as an effective ingredient, a pyrazolopyrimidinone derivative, which has good pharmacokinetic and safety profiles compared to conventional phosphodiesterase-5 (PDE-5) inhibitors.

[Technical Solution]

In order to accomplish the above objects, the present invention provides a pharmaceutical composition comprising, as an effective ingredient, \[5-\{2-propyloxy-5-\{1-methyl-2-pyrrolidinyleneamidosulfonyl\}\ phenyl\}-1-methyl-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one\] (hereinafter, referred to as "a pyrazolopyrimidinone derivative"), represented by Chemical Formula 1, below, for the novel use of the compound in the treatment of chronic heart failure.

[Chemical Formula 1]
[**Advantageous Effects**]

In accordance with the present invention, the pharmaceutical composition comprising the pyrazolopyrimidinone derivative as an effective ingredient suppresses morphological changes in chronically failing hearts. Also, the present composition reduces circulating atrial natriuretic peptide (ANP) levels, which are elevated in a pathophysiologic state of chronic heart failure, and suppresses the cardiac expression of ANP mRNA, thereby being useful as a therapeutic agent for heart failure. Further, the present composition inhibits cardiac fibrosis, thereby improving cardiac systolic and diastolic function.

Also, the pyrazolopyrimidinone derivative has a long in vivo half-life, allowing decreased administration frequency, reaches the maximal plasma level in a short time, has fewer inherent side effects, entails low danger of interaction with other drugs, and has a wide safety margin.

[**Description of Drawings**]

FIG. 1 is a graph showing that a pyrazolopyrimidinone derivative according to the present invention reduces serum ANP levels;

FIG. 2 is a graph showing that a pyrazolopyrimidinone derivative according to the present invention reduces ANP mRNA
levels in ventricular tissue; and

FIG. 3 is a graph showing that a pyrazolopyrimidinone derivative according to the present invention reduces the amount of collagen deposition in ventricular tissue.

5 [Best Mode]

The pyrazolopyrimidinone derivative according to the present invention, which is a phosphodiesterase-5 (PDE-5) inhibitor, exhibits strong and selective inhibitory activity against PDE-5, is rapidly absorbed due to its enhanced solubility, has high bioavailability and large distribution volume, and has an in vivo half-life 3 times longer than a drug acting via the same mechanism, sildenafil.

The pyrazolopyrimidinone derivative has the following physicochemical properties: it is difficult to dissolve in water but is readily dissolved in acetic acid, methanol and chloroform; it has a melting point of 158-161 °C; it has a pKAI value of about 6.5 and a pKa2 value of about 12.5; and it is not a hydrate or solvate, but is a white or light white powder.

The pyrazolopyrimidinone derivative is synthesized through a three-step process, as follows.

In brief, The first step is to prepare 4-[2-propyloxy-5-(chlorosulfonyl) benzamido] -1-methyl-3-propyl-5-carbamoyl pyrazole. 4-[2-propyloxy benzamido] -1-methyl-3-propyl-5-carbamoyl pyrazole is mixed with a predetermined amount of
chlorosulfonic acid, precooled to 0 °C. The mixture is filtered, and the filtrate is washed and dried to produce 4-[2-propyloxy-5-(chlorosulfonyl)benzamido]-1-methyl-3-propyl-5-carbamoyl pyrazole.

The second step is to prepare 4-[2-propyloxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)benzamido]-1-methyl-3-propyl-5-carbamoyl pyrazole from the pyrazole compound obtained in the first step. A predetermined amount of a dichloromethane solution of the 4-[2-propyloxy-5-(chlorosulfonyl)benzamido]-1-methyl-3-propyl-5-carbamoyl pyrazole prepared in the first step is mixed with a predetermined amount of 2-(2-aminoethyl)-1-methyl pyrrolidine with stirring at 0 °C. After the reaction is completed, the reaction mixture is diluted in dichloromethane. An organic phase is washed, dried, concentrated and filtered to produce 4-[2-propyloxy-5-(1-methyl-2-pyrrolidinylethyl amidosulfonyl)benzamido]-1-methyl-3-propyl-5-carbamoyl pyrazole.

The third step is to prepare the compound of the present invention, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyleneamidosulfonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one, from the compound obtained in the second step. A predetermined amount of the pyrazole compound synthesized in the second step is dissolved in t-butanol and mixed with a predetermined amount of potassium t-butoxide under reflux for a predetermined period of time. After the reaction is completed, the reaction mixture is cooled,
diluted, washed, and dried. The dried product is subjected to
distillation under reduced pressure, solvent removal and silica
gel column chromatography to produce a pure
pyrazolopyrimidinone derivative according to the present
invention.

The present invention relates to a pharmaceutical
composition for treating chronic heart failure, and may be
described in detail as follows.

1) The present invention provides a therapeutic agent
that suppresses cardiac morphological changes caused by heart
failure.

2) The present invention provides a therapeutic agent
that suppresses the expression of atrial natriuretic peptide
(ANP), which is elevated in failing hearts, so as to normalize
ANP levels, and that inhibits ventricular fibrosis.

3) The present invention provides a therapeutic agent for
chronic heart failure, which has better pharmacokinetic
properties and is safer than conventional phosphodiesterase-5
(PDE-5) inhibitors.

The therapeutic agent comprising the pyrazolopyrimidinone
derivative according to the present invention as an effective
ingredient may be used in general pharmaceutical dosage forms.
That is, the pyrazolopyrimidinone derivative of the present
invention may be administered in a wide variety of oral and
parenteral dosage forms upon clinical application, oral
administration being preferred in the present invention. A formulation may be prepared with generally used diluents or excipients, such as fillers, thickeners, binders, humectants, disintegrators and surfactants.

Solid formulations for oral administration may include tablets, pills, powders, granules and capsules, and are prepared by mixing the pyrazolopyrimidinone derivative compound with one or more excipients, such as starch, calcium carbonate, sucrose, lactose and gelatin. Also, the solid formulations may include, in addition to a simple excipient, a lubricant such as magnesium stearate or talc.

Liquid formulations for oral administration may include suspensions, internal solutions, emulsions and syrups. The liquid formulations may include, in addition to commonly used simple diluents, such as water and liquid paraffin, various excipients, which are exemplified by humectants, sweeteners, aromatics and preservatives. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions may be prepared with propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, Witepsol, macrogol, Tween 61, cacao oil, laurin oil and glycerinated gelatin may be used.
The dosage of the pharmaceutical composition of the present invention, comprising the pyrazolopyrimidinone derivative as an effective ingredient, may vary depending on the patient's weight, age, gender and diet, the time and mode of administration, excretion rates, and the severity of illness. Preferably, the present compound may be administered to an adult in a daily dosage of 50 to 200 mg. The daily dosage may be taken in a single dose or may be divided into several doses.

[Mode for Invention]

A better understanding of the present invention may be obtained through the following examples, which are set forth to illustrate, but are not to be construed as the limit of the present invention.

EXAMPLE: Evaluation of therapeutic effects of the pyrazolopyrimidinone derivative in an animal model of heart failure

The pyrazolopyrimidinone derivative of Chemical Formula 1 according to the present invention was evaluated to determine whether it has a therapeutic effect on heart failure, as follows.

Male Sprague-Dawley rats, weighing 220-240 g, were randomly divided into three groups: a normal control group
(Normal), a heart failure control group (CHF) and a treatment group (CHF plus cpd.l), each group consisting of seven rats. The pyrazolopyrimidinone derivative was orally administered to heart failure-developed animals of the treatment group in a dose of 30 mg/kg.

Normal control animals were subjected to a sham operation. Animals of heart failure control and treatment groups underwent a surgical abdominal incision to create an abdominal aorta-to-inferior vena cava fistula so as to artificially increase blood flow from the inferior vena cava into the right atrium. After 8 weeks, 5 ml/kg of a solvent was orally administered to the normal control and heart failure control groups for 8 weeks, and the pyrazolopyrimidinone derivative was orally administered to the treatment group at a dose of 30 mg/kg for 8 weeks. Then, rats were anesthetized with pentobarbital (50 mg/kg, i.p.), and subjected to M-mode echocardiography in order to evaluate interventricular septum wall thickness (IWT) at end-systole (S) and end-diastole (D) of the left ventricle, posterior left ventricular wall thickness (PWT), left ventricular end-systolic dimension (LVESD), and left ventricular end-diastolic dimension (LVEDD). The relative wall thickness (RWT) was calculated according to the following equation: \([\text{IWT}(D) + \text{PWT}(D)] / \text{LVEDD}\), and is given in Table 1, below.

After the echocardiographic measurements, blood samples were collected from abdominal aortas to prepare serum samples.
Serum levels of atrial natriuretic peptide (ANP) were determined, and are shown in FIG. 1. 100 mg of each of the left ventricular tissues was stored in liquid nitrogen and then subjected to RT-PCR in order to assess ANP mRNA levels. The measured ANP mRNA levels are shown in FIG. 2. The remaining parts of the tissues were fixed in 10% formalin, and stained with Masson's trichrome to detect collagen fiber in order to assess left ventricular fibrosis, and the results are given in FIG. 3. All values are expressed as mean+SD.

As shown in Table 1, short-axis M-mode echocardiographic images show that the chronic heart failure-induced rats (CHF group) had significantly greater left ventricular end-diastolic and end-systolic dimensions than normal control rats, such as an increase indicating ventricular dilatation, which is a typical sign of heart failure. Interventricular septum wall thickness at end-systole and systolic and diastolic posterior left ventricular wall thickness were significantly smaller, and this decrease results from ventricular cavity enlargement leading to ventricular wall thinning, indicating a clinically significant cardiac change. The relative wall thickness, calculated using the above equation, was also significantly decreased, and these results are consistent with the aforementioned alterations.

In aortocaval fistula rats that received the pyrazolopyrimidinone derivative for an 8-week period (treatment group), left ventricular end-diastolic and end-systolic
dimensions were significantly decreased compared to heart failure control rats (CHF group). These results indicate that the ventricular dilatation, found in chronic heart failure, was inhibited through the administration of the pyrazolopyrimidinone derivative. Also, interventricular septum wall thickness at end-systole and end-diastole and posterior left ventricular wall thickness were significantly increased, and the relative wall thickness was significantly increased, compared to the heart failure control group. These results indicate that the pyrazolopyrimidinone derivative inhibits the ventricular dilatation and a decrease in ventricular wall thickness.

FIG. 1 shows the serum levels of atrial natriuretic peptide (ANP). The chronic heart failure control group exhibited significantly increased serum ANP levels (0.040±0.004ng/ml) compared to the normal control group (0.029±0.003ng/ml). This increase was significantly decreased in pyrazolopyrimidinone derivative-receiving rats (0.033±0.003ng/ml).

FIG. 2 shows ANP mRNA levels in left ventricular tissues. The chronic heart failure control group exhibited significantly increased ANP mRNA levels (0.963±0.114) compared to the normal control group (0.607±0.169). The increased ANP mRNA levels were significantly decreased in pyrazolopyrimidinone derivative-receiving rats (0.739±0.120) compared to the heart failure group.
control group. These results indicate that ANP levels elevated by pathophysiologic changes were decreased to normal levels through the administration of the pyrazolopyrimidinone derivative.

FIG. 3 shows the amount of collagen deposition as a marker of ventricular fibrosis. The chronic heart failure control group exhibited significantly increased collagen deposition (0.928±0.228) compared to the normal control group (0.384±0.103). The increased collagen deposition was significantly decreased through the administration of pyrazolopyrimidinone derivative (0.604±0.214). These results indicate that ventricular fibrosis, causing ventricular systolic and diastolic dysfunction, was decreased by the pyrazolopyrimidinone derivative, thereby enhancing ventricular systolic and diastolic function.

TABLE 1
M-mode echocardiographic measurements for evaluating chronic heart disease induction in SD rats and therapeutic effects of the pyrazolopyrimidinone derivative on the disease

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>CHF</th>
<th>CHF+cpd.1 (30 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IWT(D) (mm)</td>
<td>1.81±0.20</td>
<td>1.56±0.09'</td>
<td>1.74±0.13''</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>8.69±0.56</td>
<td>9.75±0.85'</td>
<td>8.45±0.62''</td>
</tr>
<tr>
<td>PWT(D) (mm)</td>
<td>1.83±0.13</td>
<td>1.64±0.11'</td>
<td>1.78±0.04''</td>
</tr>
<tr>
<td>IVT(S) (mm)</td>
<td>2.83±0.17</td>
<td>2.56±0.11'</td>
<td>2.74±0.11''</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>5.43±0.31</td>
<td>6.20±0.70'</td>
<td>4.69±0.38''</td>
</tr>
<tr>
<td>PWT(S) (mm)</td>
<td>2.89±0.15</td>
<td>2.54±0.18'</td>
<td>2.80±0.10''</td>
</tr>
<tr>
<td>RWT</td>
<td>0.42±0.05</td>
<td>0.34±0.02'</td>
<td>0.42±0.05''</td>
</tr>
</tbody>
</table>
*: The CHF group exhibits a significant difference compared to the normal group (p<0.05).
**: The CHF+cpd.l group exhibits a significant difference compared to the CHF group (p<0.05).

FORMULATION EXAMPLES: Preparation of pharmaceutical formulations for oral administration

1. Preparation of powders
The compound of Formula 1 2 g
Lactose 1 g

The above components were mixed and placed in an airtight pack to produce powders.

2. Preparation of tablets
The compound of Formula 1 100 mg
Corn starch 100 mg
Lactose 100 mg
Magnesium stearate 2 mg

The above components were mixed and tabletted according to a common tablet preparation method to produce tablets.

3. Preparation of capsules

The compound of Formula 1 100 mg
Corn starch 100 mg
Lactose 100 mg
Magnesium stearate 2 mg
The above components were mixed and loaded into gelatin capsules according to a common capsule preparation method to produce capsules.
[CLAIMS]

[Claim 1]

A pharmaceutical composition for treating chronic heart failure comprising a pyrazolopyrimidinone derivative represented by Chemical Formula 1, below, as an effective ingredient.

[Chemical Formula 1]

[Claim 2]

The pharmaceutical composition according to claim 1, which inhibits cardiac morphological changes in chronic heart failure.

[Claim 3]

The pharmaceutical composition according to claim 1, which inhibits ventricular cavity enlargement and ventricular wall thickness change in chronic heart failure.
[Claim 4]
A method of treating chronic heart failure comprising administering a pyrazolopyrimidinone derivative represented by Chemical Formula 1, below, to a patient in need of such treatment in a therapeutically effective amount.

[Chemical Formula 1]

[Claim 5]
A use of a pyrazolopyrimidinone derivative represented by Chemical Formula 1, below, in manufacture of a pharmaceutical formulation for treating chronic heart failure.

[Chemical Formula 1]
Serum ANP level

ANP (ng/mL)

Normal  CHF  CHF+cpd.1

0.00  0.01  0.02  0.03  0.04  0.05

*   **
FIGURE 2

ANP mRNA expression

Arbitrary unit

ANO/β-actin

Normal

CHF

CHF+cpd.1
FIGURE 3

LV fibrosis

% area of collagen

Normal  CHF  CHF+cpd.1
A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/519(2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 8 as above

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKIPASS(KIPO internal), Pubmed, Google

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>see the whole document especially page 3, claim 1</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td>KR 10-353014 B1 (DONG-A PHARMACEUTICAL CO., LTD) 18 September 2002</td>
<td>1-3, 5</td>
</tr>
<tr>
<td></td>
<td>see the whole document, chemical formula 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see the whole document</td>
<td></td>
</tr>
</tbody>
</table>

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

Further documents are listed in the continuation of Box C

See patent family annex

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

27 OCTOBER 2008 (27.10.2008)

Date of mailing of the international search report

27 OCTOBER 2008 (27.10.2008)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, 139 Seonsa-ro, Seogu, Daejeon 302-701, Republic of Korea

Authorized officer

BAN, Yong Byung

Facsimile No 82-42-472-7140

Telephone No 82-42-481-5605

Form PCT/ISA/210 (second sheet) (My 2008)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **Claims Nos 4**
   - because they relate to subject matter not required to be searched by this Authority, namely
   - Claim 4 pertain to methods for treatment of the human or animal body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39 l(iv) of the Regulations under the PCT, to search.

2. **Claims Nos**
   - because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically.

3. **Claims Nos**
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6-4(a).

### Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. **As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.**

2. **As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.**

3. **As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.**

4. **No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.**

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.
## INTERNATIONAL SEARCH REPORT
### Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>KR 10-358083 B1</td>
<td>25.10.2002</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69909818 T2</td>
<td>27.05.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1129093 T3</td>
<td>20.10.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1129093 A1</td>
<td>05.09.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1129093 B1</td>
<td>23.07.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2204169 T3</td>
<td>16.04.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1039328 A1</td>
<td>25.06.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3577630 B2</td>
<td>13.10.2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20000035324 A</td>
<td>26.06.2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 511015 A</td>
<td>26.09.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1129093 T</td>
<td>31.12.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2220145 C2</td>
<td>27.12.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TR 200101335 T2</td>
<td>21.09.2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6583147 B1</td>
<td>24.06.2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 00-27848 A1</td>
<td>18.05.2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1092720 B1</td>
<td>12.01.2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 0018667 DO</td>
<td>13.09.2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 9924042 DO</td>
<td>15.12.1999</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (My 2008)